Lumos Pharma Inc. traded at $7.69 this Friday July 1st, decreasing $0.01 or 0.13 percent since the previous trading session. Looking back, over the last four weeks, Lumos Pharma Inc. lost 0.13 percent. Over the last 12 months, its price fell by 24.61 percent. Looking ahead, we forecast Lumos Pharma Inc. to be priced at 7.13 by the end of this quarter and at 6.57 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
7.69
Daily Change
-0.13%
Yearly
-24.61%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Agenus 1.96 0.02 1.03% -64.49%
Bristol-Myers Squibb 76.84 -0.16 -0.21% 14.77%
Capricor Therapeutics 3.68 0.19 5.44% -26.10%
Celldex Therapeutics 22.70 -4.26 -15.80% -32.94%
Idera Pharmaceuticals 0.44 -0.02 -4.58% -62.56%
Incyte Corp 77.67 1.70 2.24% -7.07%
Eli Lilly 324.71 0.48 0.15% 38.79%
Merck & Co 92.42 1.25 1.37% 17.58%
Nektar Therapeutics 3.75 -0.05 -1.32% -78.08%
Lumos Pharma Inc. 7.69 -0.01 -0.13% -24.61%
Pfizer 52.31 -0.12 -0.23% 31.66%
Prothena 27.89 0.74 2.73% -49.72%
Sarepta Therapeutics 75.71 0.75 1.00% 0.62%
Vascular Biogenics 1.63 0.02 1.24% -27.23%
Intrexon 1.41 0.07 5.22% -78.04%

Indexes Price Day Year
USND 11128 99.11 0.90% -23.99%
US2000 1728 19.77 1.16% -25.07%

Lumos Pharma Inc.
Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, acquiring, developing and commercialization of products, and therapies for people with rare diseases. The Company's lead product candidate is LUM-201, a therapy for pediatric growth hormone deficiency (PGHD) and other rare endocrine disorders. LUM-201 stimulates growth hormone (GH) through the GH secretagogue receptor. Its product provides a differentiated mechanism of action to treat rare endocrine disorders by increasing the amplitude of endogenous and pulsatile GH secretion. LUM-201 is an orally administered small molecule, which is a GH secretagogue for rare endocrine disorders where injectable recombinant human growth hormone (rhGH) is approved. The Company’s pipeline features development programs in rare diseases associated with growth hormone deficiencies.